查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球糖尿病神经病变市场 - 2023-2030年
市场调查报告书
商品编码
1285064

全球糖尿病神经病变市场 - 2023-2030年

Global Diabetic Neuropathy Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球糖尿病神经病变市场在2022年达到37.754亿美元，预计到2030年将见证有利可图的增长，达到62.981亿美元。在预测期间（2023-2030年），糖尿病神经病变市场预计将呈现6.7%的复合年增长率。

糖尿病神经病变是由于糖尿病引起的神经恶化，通常会导致脚或小腿的疼痛和感觉丧失。根据神经病变的影响，在不同的身体部位如臀部、手腕和背部都会遇到疼痛。有不同类型的神经病变，如局灶性神经病变、近端神经病变、周围神经病变和自主神经病变。

糖尿病患者和老年人口数量的增长，以及各政府组织不断增加的资助倡议，都在推动全球糖尿病神经病变市场的增长。

市场动态

不断增长的老年人口预计将在预测期内推动全球糖尿病神经病变市场。

神经病在65岁以上的人中非常典型，而且随着年龄的增长，神经病的比例也在上升。因此，老年人口的增长正在推动全球糖尿病神经病变市场。例如，根据联合国发布的《2022年世界人口前景》，80岁或以上的人的数量预计将增长三倍，从2022年的1.57亿增加到2050年的4.59亿。

各种政府组织不断增加的资金为全球糖尿病神经病变市场提供了潜在的增长机会

各个政府组织不断增加的资金倡议正在为全球糖尿病神经病变市场提供有利可图的增长机会。例如，美国卫生与公众服务部通过印第安人健康服务，为2023财政年度的印第安人特别糖尿病计划（SDPI）提供1.39亿美元的资金，为美国阿拉斯加和印第安原住民社区提供糖尿病预防和治疗援助。

COVID-19影响分析

COVID-19分析包括COVID前情景、COVID情景和COVID后情景以及定价动态（包括大流行期间和之后的定价变化与COVID前情景的比较）、需求-供应谱（由于贸易限制、封锁和后续问题造成的需求和供应变化）、政府倡议（政府机构振兴市场、部门或行业的倡议）和制造商战略倡议（这里将涉及制造商为缓解COVID问题所做的努力）。

俄乌战争影响分析

在乌克兰，慢性病患者目前遇到的问题是由于缺乏医疗支持，如慢性病的药物，而此时，由于入侵，电力、供暖和清洁水等基本需求没有得到关注。因此，俄乌战争对全球糖尿病神经病变市场产生了负面影响。

全球经济衰退影响分析

医疗保健行业并非完全不受经济衰退的影响，因为在过去的金融衰退中，医疗保健机构应该进行裁员和招聘。这说明该企业与不同行业相比，确实管理得更好。然而，随着通货膨胀的到来，经济衰退的威胁给市场带来了风险。

由于全球发达国家的高通胀率，有关持续衰退的压力程度扩大，在过去两年中出现了全方位的价格波纹。

人工智能影响分析

人工智能预计将对全球糖尿病神经病变市场产生积极影响，因为随着人工智能处理大数据池的能力，结合病人的经验可以直接带来预测性的好处，使医疗保健生态系统能够暴露出需要修改的病人护理的关键层面。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按类型分析
  • 按药物类型分类
  • 按分销渠道分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 越来越多的糖尿病病例
      • 市场的发展
    • 限制因素
      • 严格的监管机构
    • 机会
    • 政府倡议
    • 影响分析

第五章：行业分析

  • 波特的五力分析
  • 监管分析
  • 价格分析
  • 专利分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • 后COVID-19及未来的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第7章 ：俄罗斯-乌克兰战争分析

第八章：全球经济衰退分析

第九章：人工智能分析

第十章：按类型

  • 周边神经病变
  • 自主神经病变
  • 近端神经病变
  • 局部神经病变

第十一章：按药物类别分类

  • 抗抑郁药
  • 抗惊厥剂
  • 阿片类药物
  • 非甾体类药物
  • 其他

第12章：按分销渠道分类

  • 医院和诊所药房
  • 零售药店和商店和商店
  • 网上药店

第十三章 ：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第十四章：竞争格局

  • 竞争格局
  • 市场份额分析
  • 合併和收购分析

第十五章 ：公司简介

  • Depomed Pharma
    • 公司概述
    • 类型组合和描述
    • 财务概况
    • 主要发展情况
  • Eli Lilly and Company
  • Daiichi Sankyo
  • Teva Pharmaceutical Industries Ltd.
  • Xenoport
  • Grunenthal
  • Johnson and Johnson
  • Pfizer
  • GlaxoSmithKline
  • Boehringer Ingelheim

第16章 ：附录

简介目录
Product Code: PH258

Market Overview

The global diabetic neuropathy market reached USD 3,775.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 6,298.1 million by 2030. The diabetic neuropathy market is expected to exhibit a CAGR of 6.7% during the forecast period (2023-2030).

Diabetic neuropathy is the deterioration induced to the nerve because of diabetes, which usually causes pain and loss of sensation in the feet or lower legs. The pain can be encountered in different body parts like hips, wrists, and back based on the impact of neuropathy. There are different types of neuropathy like focal neuropathy, proximal neuropathy, peripheral neuropathy, and autonomic neuropathy.

The growing number of diabetes patients and the geriatric population, and increasing funding initiatives from various government organizations are driving the global diabetic neuropathy market growth.

Market Dynamics

The Growing Geriatric Population is Expected to Drive The Global Diabetic Neuropathy Market Over The Forecast Period.

Neuropathies are exceptionally typical in individuals over 65 years old and their preponderance upsurges with age. Thus, the growing geriatric population is driving the global diabetic neuropathy market. For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.

The Increasing Funding from Various Government Organizations is Providing the Global Diabetic Neuropathy Market with Prospective Growth Opportunities

The increasing funding initiatives from various government organizations are presenting the global diabetic neuropathy market with lucrative growth opportunities. For instance, the U. S. Department of Health and Human Services, via the Indian Health Service, is funding $139 million for the Fiscal Year 2023 Special Diabetes Program for Indians (SDPI) to deliver diabetes prevention and therapy assistance for American Alaska and Indian Native communities.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

The issues that are currently being encountered by individuals with chronic conditions in Ukraine are increased by a deficiency of medical support such as medications for chronic disorders at a time when fundamental requirements like electricity, heating, and clean water are not being attended, to because of the invasion. Thus, the Russia-Ukraine war has negatively impacted the global diabetic neuropathy market.

Global Recession Impact Analysis

The healthcare industry is not completely invulnerable to a recession, as healthcare organizations supposed layoffs and hirings in past financial downturns. That remarked the enterprise does manage better compared to different sectors. Yet, the threat of recession risks the market as inflation succeeds.

The extended degree of stress concerning the ongoing recession as the high inflation in developed countries worldwide has transpired in an all-around price ripple through the past two years.

Artificial Intelligence Impact Analysis

AI is anticipated to hold a positive influence on the global diabetic neuropathy market as with AI's capacity to process big data pools, combining patient experiences can direct to predictive benefits, enabling the healthcare ecosystem to expose key dimensions of patient care that need revision.

Segment Analysis

The global diabetic neuropathy market is segmented based on type, drug class, distribution channel, and region.

The NSAIDS Segment is Estimated To Hold a 35.4% Share of the Global Market

The NSAIDs segment is estimated to hold the largest share of the global diabetic neuropathy market, owing to the easy availability of the NSAIDs as are over the counter and hence, readily available for patients in their residents. Additionally, majority of the NSAIDs have their generic formulations obtainable in the market making them affordable and these drugs deliver quick relief without any severe side effects.

Geographical Analysis

Europe is Estimated to Hold the Second-Largest Share of the Global Diabetic Neuropathy Market During the Forecast Period

Owing to the increasing incidence of diabetes, Europe is estimated to hold about 26.3% of the global diabetic neuropathy market. For instance, according to WHO, there are over 60 million individuals with diabetes in the European region, or nearly 10.3% of males and 9.6% of females aged 25 years and above. The preponderance of diabetes is rising among all generations in the European region, primarily because of the increase in overweight and obesity, unhealthy food consumption, and less physical inactivity.

Competitive Landscape

The major global players in the market include: Depomed Pharma, Eli Lilly, Daiichi Sankyo, Teva Pharmaceutical Industries Ltd., Xenoport, Grunenthal, Johnson and Johnson, Pfizer, GlaxoSmithKline, and Boehringer Ingelheim among others.

WHY PURCHASE THE REPORT?

  • To visualize the global diabetic neuropathy market segmentation based on type, drug class, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of diabetic neuropathy market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global diabetic neuropathy market report would provide approximately 53 tables, 54 figures, and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Cases of Diabetes
      • 4.1.1.2. Market Developments
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Authorities
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Analysis

10. By Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.1.2. Market Attractiveness Index, By Type
  • 10.2. Peripheral Neuropathy
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Autonomic Neuropathy
  • 10.4. Proximal Neuropathy
  • 10.5. Focal Neuropathy

11. By Drug Class

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.1.2. Market Attractiveness Index, By Drug Class
  • 11.2. Anti-Depressant
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Anti-Convulsant
  • 11.4. Opioids
  • 11.5. NSAIDs
  • 11.6. Others

12. By Distribution Channel

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.1.2. Market Attractiveness Index, By Distribution Channel
  • 12.2. Hospitals and Clinics Pharmacy
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Retail Pharmacy and Stores and Stores
  • 12.4. Online Pharmacy

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.6.1. The U.S.
      • 13.2.6.2. Canada
      • 13.2.6.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.6.1. Germany
      • 13.3.6.2. The U.K.
      • 13.3.6.3. France
      • 13.3.6.4. Italy
      • 13.3.6.5. Spain
      • 13.3.6.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.6.1. Brazil
      • 13.4.6.2. Argentina
      • 13.4.6.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.6.1. China
      • 13.5.6.2. India
      • 13.5.6.3. Japan
      • 13.5.6.4. Australia
      • 13.5.6.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Depomed Pharma
    • 15.1.1. Company Overview
    • 15.1.2. Type Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Eli Lilly and Company
  • 15.3. Daiichi Sankyo
  • 15.4. Teva Pharmaceutical Industries Ltd.
  • 15.5. Xenoport
  • 15.6. Grunenthal
  • 15.7. Johnson and Johnson
  • 15.8. Pfizer
  • 15.9. GlaxoSmithKline
  • 15.10. Boehringer Ingelheim

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us